Form 4: Theravance Biopharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Rick E Winningham, CHIEF EXECUTIVE OFFICER and a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
Summary
- Disposition to the issuer: disposed of 1,382,272 Ordinary Shares on September 23, 2026; holds 228,750 after (Direct).
- Disposition to the issuer: disposed of 151,875 Ordinary Shares on September 23, 2026; holds 76,875 after (Direct).
- Disposition to the issuer: disposed of 76,875 Ordinary Shares on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 23,400 Ordinary Shares on September 23, 2026 (Indirect).
- Disposition to the issuer: disposed of 92,567 Ordinary Shares on September 23, 2026 (Indirect).
- Disposition to the issuer: disposed of 515,000 Share Option (Right to Buy) on September 23, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rick E Winningham — Director, Officer (CHIEF EXECUTIVE OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 1,382,272 | — | — | 228,750 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 151,875 | — | — | 76,875 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 76,875 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 23,400 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 92,567 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 515,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Disposition to the issuer (1,382,272 shares) |
| 2026-09-23 | Disposition to the issuer (151,875 shares) |
| 2026-09-23 | Disposition to the issuer (76,875 shares) |
| 2026-09-23 | Disposition to the issuer (23,400 shares) |
| 2026-09-23 | Disposition to the issuer (92,567 shares) |
| 2026-09-23 | Disposition to the issuer (515,000 shares) |
Keywords
insider transaction, Form 4, TBPH, Theravance Biopharma, Inc., neutral, Rick E Winningham
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.